Crew Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-2,956
Closed -$220K 98
2022
Q2
$220K Sell
2,956
-699
-19% -$52.5K 0.28% 84
2022
Q1
$329K Sell
3,655
-14,922
-80% -$1.38M 0.32% 75
2021
Q4
$2.08M Sell
18,577
-695
-4% -$83.8K 1.76% 18
2021
Q3
$2.42M Buy
19,272
+882
+5% +$114K 2.25% 16
2021
Q2
$2.49M Sell
18,390
-902
-5% -$119K 2.33% 15
2021
Q1
$2.62M Buy
+19,292
New +$2.89M 2.61% 9

Other funds holding XBI

Crew Capital Management's XBI Position: Q3 2022 in Review

Crew Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2022, closing a stake of 2,956 shares — an estimated $220K sold.

Crew Capital Management first reported a position in XBI in Q1 2021 and held it in 6 quarters. The position peaked at $2.62M in Q1 2021. 704 funds tracked by Wall St. Rank hold XBI as of Q3 2022.

  • Crew Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2022 after selling out during the quarter.
  • Crew Capital Management sold 2,956 State Street SPDR S&P Biotech ETF shares in Q3 2022, an estimated $220K.
  • Crew Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2021 and held it in 6 quarters.
  • Crew Capital Management's State Street SPDR S&P Biotech ETF position peaked at $2.62M in Q1 2021.
  • 704 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2022.

Based on Crew Capital Management's 13F filing for Q3 2022, filed 20 Oct 2022.